have identified CHRDL1, NEFH, TAGLN, and SYNM as novel diagnostic biomarkers for BPH and PCa, which aid in early diagnosis, treatment, and assessment of immunotherapeutic responses. This evidence concerns the gene TAGLN and benign prostatic hyperplasia.